The Mall building (at the bottom of the model) comprises of 11 levels :-


(a) Level 1 (Mall Ground Floor) - Retail units to be retained by developer for rental income;

(b) Level 2 (Mall Upper Ground Floor) - Retail units for sale (Theme America);

(c) Level 3 (Mall First Floor) - Retail units for sale (Theme Europe);

(d) Level 4 (Mall Second Floor) - Retail units for sale (Theme Oceania);

(e) Level 5 (Mall Third Floor) - Retail units for sale (Theme Asia);

(f) Level 6 (Mall Fourth Floor) - Retail units for sale (Theme Africa);

(g) Level 7 to 10 (Car parks); and

(h) Level 11 (World Museum) - Not for sale. Visitors pay entrance fees.

http://klse.i3investor.com/blogs/icon8888/62027.jsp

Also gadang provide land, do they capitally involved?

Capital 21 idea is good, location super bad. Such concept if put at jln wong ah fook, will even beat city square. Current location, and if hatten do not have control over tenants, or type of shops they are going to bring in, visitors will only visit once or twice, just to look at the interior, then bye bye. Chances of failure is super high. Good thing: hatten and gadang have the power to build it up and not cabut. Just that capital 21 cannot perform at all due to location.

No need too long, few years back, when ringgit still strong, do you miss malaysia boleh? Malaysia boleh is just an useless slogan, when thing good, ppl forget, when things bad, ppl rmb back the good old day. Malaysia boleh will not cure malaysia fundamental racial problem, talking about unite people, bangsa johor (if sultan wishes able to implement) able to do a much greater job than malaysia boleh.

Aiyoh, such petite return when buy at safe time, better buy bluechips. N such company harder to time the buying time when it is safe bcoz the correction can be quite volatile, u think safe liao, then drop somemore for you. Now easier to time, straight bankrupt return 0, or tiny good news or big good news. Im sane, i knew the risk, no margin thx. Like go casino, u pinjam ah long to gamble meh?

Meathere: "After few months when all the dust settled, price stabilized; and there some confirmation IF this company has possibility for turn around or buy out then MAYBE can enter to take the risk. "

Your suggestion cannot pakai, ppl enter now certainly they already knew the worst, to compensate their high risk, they want high return. When everything settle down, how much return you can gain for buying at safe time? Mayb you need to buy at 15 cents a shares or more and volatile btw 1-2 cents.... i would rather bet and lose it all than buy into such safer risk and earn petite.

Calvin woke up in gold mine, hcpc woke up in denial. Share price explain everything, time to sell or continue to hold??

Retail is not the future in china, alibaba too strong. Go nyse buy baba.

山上怎么挖地下水?没道理。

sell la, no eyes see
c liao lah genting
hk genting ,sg genting ,my genting all lose $$$, then die lah
no china vip come sure die, msia kaki where got $$$ to gamble

No one knows, even those with pharmacology phd will not know. But to date, those big pharma that targetting on amyloid beta yield no even a single positive result. N big pharma already changing their focus to tau protein related drug...more and more latest experiment result showing tau is the culprit. If tau is not the answer, it will be a dark age to mankind, research will not know where to start next.

吃穿用度都家里， 可能可以存那么多。接下来就看她怎么说她投资亏钱的故事，太小气爱钱，投资时难免跟情绪走。

Im still interested betting on the coming trial result... but for now, wait until it drop gao gao. Upper 7 i will get in big, finger crossed, come sell genting, the trial failed, sell it, dont wait.

Lilly's new studies suggest relationship between tau pathology and progression of Alzheimer's disease
Indianapolis, Indiana
Friday, July 29, 2016, 15:00 Hrs [IST]
Eli Lilly and Company announced results from two distinct analyses of a phase 2 study using the tau imaging agent flortaucipir ([18F] AV-1451) that evaluated the relationship between tau tangles and the progression of Alzheimer's disease.

The first analysis, "Evolution of [18F] AV-1451 PET Tau Signal: Interim Analysis of an 18 Month Phase 2 Study," suggested the presence of tau tangles increased significantly over an 18-month period, consistent with ongoing cognitive decline in beta-amyloid positive patients. Further, patients with more tau at baseline accumulated tau at a faster rate, indicating the development of Alzheimer's disease accelerates as it progresses.1 The second analysis, "The Relationship of [18F] AV-1451 PET Tau Images to Changes in Cognition over Time," suggested a correlation between the location of tau in the brain and progression of cognitive decline in beta-amyloid positive patients. These findings were presented today at the Alzheimer's Association International Conference 2016 (AAIC 2016) in Toronto, Canada.

"These data are exciting because they suggest new insights into the relationships between tau deposits and the progression of Alzheimer's disease," said Mark Mintun, M.D., chief medical officer, Avid Radiopharmaceuticals, a wholly owned subsidiary of Lilly. "We hope these results can help guide future studies to further our understanding of the mechanisms of Alzheimer's disease and speed the development of treatments."

The primary objective of the first analysis was to characterize the rate of change in the tau signal in Alzheimer's disease to follow disease progression. The primary objective of the second analysis was to understand how the uptake patterns of flortaucipir relate to cognitive performance. Flortaucipir is Lilly's phase 3 tau positron emission tomography (PET) imaging agent, an investigational chemical entity being studied for the imaging of tau pathology. Tau imaging agents may enable researchers to noninvasively examine the degree and extent of tau pathology in the brain, quantify changes in tau deposition over time, evaluate its relation to cognition and assess the efficacy of Alzheimer's disease therapeutics. As a marker of neurodegeneration, tau imaging may serve as an adjunct tool to aid in diagnosis, as well as in disease staging. A tau-PET tracer could potentially also allow for a selection of pathology-positive individuals and monitor the effectiveness of therapy.

"This is the first time an analysis has shown a correlation between tau tangles and cognitive decline in patients living with Alzheimer's disease," said Michael Devous, Ph.D., vice president, Avid Radiopharmaceuticals, a wholly owned subsidiary of Lilly. "As tau pathology is considered a biomarker of cognitive decline, understanding the patterns in the tau signal specific to Alzheimer's disease might be useful in predicting disease progression."

Alzheimer's disease, the most common form of dementia, causes progressive decline in memory and other aspects of cognition. Beta-amyloid plaques and tau tangles are two known hallmark pathologies of Alzheimer's disease and each works in different ways. Tau protein forms into neurofibrillary tangles, which are abnormal collections of twisted protein threads found inside nerve cells. These tangles start in the areas of the brain important for memory, then proceed throughout the rest of the brain as symptoms progress.

If stock dint give dividend, then free to grab isnt?

Too risky to put hope on taurx at the moment. Hopefully their nxt coming trial result yield the same outcome for monotherapy group, only then FDA will look into it although overall trial failed. If not, Genting investment all flush to longkang.

Fx lee, everyone found out already, only you didnt. In ur profile wrote Investing experience Advanced Risk profile High..... how come blur like sotong?

Jn88, I wrote out other possibilities, feel interested can refer to my past few postings. More information needed before i can assess chances of getting thru FDA.

Kinfatt999, u r on the bus, u c liao? Ur comment can be more contributive? Too much personal expression, irritating.

If those on tau group able to show on brain scan they have lesser brain atrophy, then no matter how similar their cognitive function are with placebo group, FDA will look into it.....no drug to date able to reduce brain damaging.

Im afraid on the false positive which make the only hope in this trial vanish. Normally when a trial fail, they will play with wording, twist and turn to make them seem still got hope. Is there a group taking 100% placebo? Why they do not comparw this group with the monotherapy group, are they trying to hide and try to make positive result by comapring with overall placebo group? Fishy fishy.

Fx lee, answer is all up there.

Mikkel low, market will reward those who dare, when you start to feel safe, the correction already over.

Heng liang, u said 173-178 is a good buy, now even lower, buying?

If they can compare the group of monotherapy vs placebo monotherapy (receiving only placebo) and the statistic show significant differences, then the chances will be much much higher.

However if brain scan and other indicator prove otherwise, thing may change. Who know, maybe brain scan show brain atrophy reduction significantly but cognitive function remain impair and down... this kind of anomaly always exist in real world.

My pinch of salt: why the minority able to have 85% reduction rate? or do monotherapy is the hope for alzheimer?

Many possibilities, it may due to those symptoms controlling drug inhibit LMTX from working properly inside the brain, render monotherapy is sufficient to delay the disease progression. This is the positive possibility.

Negative one will be， the reason why ppl do not receive other symptom control treatment is because they are still new to the disease. Those that new and never received any treatment were recruited to the trial and they will take much longer before symptom starting to show, brain starting to deteriorate. So in effect, the 85% success maybe due to those brain still fresh and will take longer...compare to those old brain that might already took the symptom control medicine for years.

Correct me if im wrong, i think alzheimer progress differently on different stage, those early stage will be much slower..but when reach a criticlal point, there will be no return and the disease will progress faster. It will be biased if the monotherapy group represent the early stage patient group patient. Result that we see, slower progression in monotherapy group when this early stage group patient by nature already slow in progress with or without any drug. FDA will took that into account and the possiblity for approval will be slim.

Just went to check up again: If currently taking an acetylcholinesterase inhibitor and/or memantine at the time of Screening, the subject must have been taking such medication(s) for ≥3 months. The dosage regimen must have remained stable for ≥6 weeks and it must be planned to remain stable throughout participation in the study.

If you are a member of FDA committee, will you vote to approve it?

Aikinlai making sense. Gamers in general not rich, restaurant still can.

No he just woke up to the risk involved in this bipolar event.

They cant, they bankrupt, ppty price drop, rich man pick up. Then economy getting better, poor will pay loan for life to buy de bcoz ppty will have another uptrend many years to go.

What lemon juice deleted? 1doit no brain commwnt?

Delay announcement is not a good news, the longer it delay, the higher chances it fail.

Really, how to crash? If GFC again, central bank will print money again to counter the drop. The worse may end up be the best.

Tan kong han bet is rather small if he knew the result. Nope i dont think he got insider news, his education background doesnt supprt that nor he directly involve in the trial. His position in taurx the most is just attend meeting twice yearly and earn few hundred thousand dollar as director...that all. Every invested company have the rights to place their ppl in the company, what about temasek or dundee ppl? Any action?

Give a timeline weiiii....want to say you wrong also cannot. I say physical metal will have biggest bubble, we can create a machine to make any metal cheap after we know how to make use of higgs bosons. One day the bubble will happen, prove me wrong la.

其实新加坡也发生过，私人公寓，每间700-800千，每个人也讲泡沫，新加坡人买不起。而且那时我看图表也是很惨，画线的话，应该会跌到很便宜才对。结果停在那里一阵子，一下子全部就过百万了，更加难以负担，但也没爆，金融也没跨，政府出来打房几次，泡沫也没爆。。。。我看原因是新加坡那几年人民平均收入都在涨，有钱人更有钱，热钱涌进，那时候看图表，没把未来会有的变动考虑进来。马来西亚也一样，1mdb，恐怖袭击威胁只是暂时。你也要看鸡鸡政府有没有把重大经济决策弄对，市场有没有更大，政治会不会有其他变数。其实当人民收入起10%时，房价会起更多的。。。收入不会起? 问你40年前，你赚多少，二十年前你又转多少? 未来RCEP,TPP会对经济带来多大影响，真的现在就下定论，太早了。

数据很容易骗人，你看到的是数据的现在情况，然后就自己画图讲以后图的线会一直下，挺天才的骗人法。现在市场都没有信心，M3怎么升? 央行放低放贷成本就说明他们有在关注。其实马来西亚金融结构没有问题，泡沫问题还吹不够大，真真的危机还不是现在。我看爆，最多最惨20%就可以进场接盘了，顶多就是一个调整期。房地产不是平等的，有钱人决定价格走向，会跌多惨就要看有钱人的心思。

Any opinion what warrant will look like if the trial fail?

If trial fail, how warrant price will go? If genting mothe share is 8.50?

Hng33, remember is blinded trial, in between evaluation, trial conductor do not know what drug they get until the trial end, they will unblind it. Suggest listing on nasdaq cost no money, one have to ask, if so promising, why it was not bought over by big pharma? From experience, just before the result is out, there will be abnormal share price movement, this is somerhing need to be watched out. Not suggesting anything, do your own due diligence.

Up_down Depens on how you see, good to have foreign fund, not down how to buy in? I ady offload, now is a good time to have bad news. I strongly welcome them to join klse, n i will get out before they do.

Hng33, you need to beware of the risk, if fail, downside can be 10% or mother share back to RM8 or below bcoz 1mdb/najib got pattern again recently, overall market is falling. Still the outcome is worth risking. I remember i invest a small timer cancer drug company, was 65 cent, after trial fail, 8 cents, not even have time to run, just 65 straight to 8. Luckily i knew the risk, willing to lose it all n not feel the pain.

After phase 3 trial success, it will need to get FDA committee approval, it will be a 10 committee members voting system, get majority vote, the drug is anytime on the market. FDA is important because many countries like malaysia or even singapore, by name they got their own gov drug review committee....but pretty much they do nothing de, just FDA say what is what. Other notable committee including TGA from Australia, NICE from UK....then EU got their own, cant remember.

Do happen before successful ph3 trial being rejected by FDA bcoz of side effect concern....sometime after post market also taken down on ph 4...like vioxx incident.

Hng33, great to hear that you finally dig out what phase 3 trial is. Do u regret fry share on genting bhd when major event about to happen?

"该行认为，TauRx选择参与该会议，释放了正面讯号。同时，该行在细读阿兹海默论坛意见后，引述舆论表示该药物的确改善了病人认知能力。"

This line is epic, make me think those so call profession analyst by 马银行"研究" analyst only know skin deep. They get their understanding and opinion from other forum and they feel they are in a position to comment, and quote that the drug improve patient cognitive function.

Personally i do not think they have any insider information, or even bother to hire undercover to spy on the trial or give kopi money to trial doctor. I think they just know the whole impact very recently, as recent as this year, i think im way more qualify to be their chief analyst.

I really wonder why nobody talking taurx few years back? I already paying attention back in 2013 when genting just newly invested taurx and potential pharmaceutical companies all the while targetting the wrong protein , that time i remember clearly kenanga in their keynote about this investment is not worth anything! They are just too clever to know anything about drug, they are analysts anyway.

"Janus Mun: trial until 2017....wont get approved lastest even by 2020....FDA very stringet on all drugs.....not easily get approved."

The trial that you look at is <Open-Label Study of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)>, that will be concluded by 2017. The trial that we are looking at is the phase 3 trial that concluded this year.

Not everything FDA is strigent, if it is a breakthrough, they have fast tracking and quick approval. After phase 3 trial concluded, committee approved, within a year can out to the market already. Two to three years approval duration is for those non life threathening illnesses, or those biosimilar drugs that the FDA has no urgency to push it to the market. Cancer immunotherapy like Keytruda, I remember phase 3 trial result was out in end of 2013, 2nd quarter of 2014 already available on the market.

Fahmizee and Hng33 at first look like genius, buy sell buy sell lock in small profit...now want to get back in also takut....hahaha few weeks ago, why dont just buy it low, sit down and relax, like what i did. 50% upside or 100% wd upside need how many time 1-2% buy sell profit to achieve? why so foolish? want bet dare abit la. now so high liao baru want to bet, i also takut.

Lesson to be learnt: only short term trading on stocks that has NO major news coming in. Not on something that going to have major event.

Hng33, waiting for genting to drop back? Not takut the ship sailing any time soon?